Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Tsao

Showing results (11-20 of 49) with videos related to

Pageof 5
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 1, 2009
Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimenStuart Salmon, Heidi Chen, Shuo Chen, et al.
International Journal of Radiation Oncology, Biology, Physics|December 18, 2017
Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 StudyMelenda D Jeter, Daniel Gomez, Quynh-Nhu Nguyen, et al.
Lung Cancer (Amsterdam, Netherlands)|May 12, 2018
Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line settingMartin Reck, Marina Chiara Garassino, Martina Imbimbo, et al.
Cancer|September 30, 2024
The American Cancer Society National Lung Cancer Roundtable strategic plan: Methods for improving turnaround time of comprehensive biomarker testing in non-small cell lung cancerSinchita Roy-Chowdhuri, Haresh Mani, Adam H Fox, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 12, 2024
Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFR Germline MutationsKelsey Pan, Jennifer Owens, Yasir Elamin, et al.
The Annals of Thoracic Surgery|October 24, 2007
Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesotheliomaDavid C Rice, Craig W Stevens, Arlene M Correa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2017
Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching AnalysisDavid B Nelson, David C Rice, Jiangong Niu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 28, 2013
Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trialAlda L Tam, Edward S Kim, J Jack Lee, et al.
The Lancet. Oncology|September 10, 2022
Effect of dexamethasone on dyspnoea in patients with cancer (ABCD): a parallel-group, double-blind, randomised, controlled trialDavid Hui, Veronica Puac, Zeena Shelal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2008
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinibVincent A Miller, Gregory J Riely, Maureen F Zakowski, et al.
Pageof 5

Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 1, 2009
Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimenStuart Salmon, Heidi Chen, Shuo Chen, et al.
International Journal of Radiation Oncology, Biology, Physics|December 18, 2017
Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 StudyMelenda D Jeter, Daniel Gomez, Quynh-Nhu Nguyen, et al.
Lung Cancer (Amsterdam, Netherlands)|May 12, 2018
Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line settingMartin Reck, Marina Chiara Garassino, Martina Imbimbo, et al.
Cancer|September 30, 2024
The American Cancer Society National Lung Cancer Roundtable strategic plan: Methods for improving turnaround time of comprehensive biomarker testing in non-small cell lung cancerSinchita Roy-Chowdhuri, Haresh Mani, Adam H Fox, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 12, 2024
Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFR Germline MutationsKelsey Pan, Jennifer Owens, Yasir Elamin, et al.
The Annals of Thoracic Surgery|October 24, 2007
Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesotheliomaDavid C Rice, Craig W Stevens, Arlene M Correa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2017
Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching AnalysisDavid B Nelson, David C Rice, Jiangong Niu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 28, 2013
Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trialAlda L Tam, Edward S Kim, J Jack Lee, et al.
The Lancet. Oncology|September 10, 2022
Effect of dexamethasone on dyspnoea in patients with cancer (ABCD): a parallel-group, double-blind, randomised, controlled trialDavid Hui, Veronica Puac, Zeena Shelal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2008
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinibVincent A Miller, Gregory J Riely, Maureen F Zakowski, et al.
Pageof 5